Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Afinitor

Afinitor 2.5 mg tablets Afinitor 5 mg tablets Afinitor 10 mg tablets · Abschnitt 4.5 · PDF-Seite 9

HOS-210305 · Präparat HOS-154501

Active substance by Interaction – Change in Recommendations concerning interaction Everolimus AUC/Cmax co-administration Geometric mean ratio (observed range) Potent CYP3A4/PgP inhibitors Ketoconazole AUC ↑15.3-fold Concomitant treatment of Afinitor (range 11.2-22.5) and potent inhibitors is not Cmax ↑4.1-fold recommended. (range 2.6-7.0) Itraconazole, posaconazole, Not studied. Large increase in voriconazole everolimus concentration is Telithromycin, expected. clarithromycin Nefazodone Ritonavir, atazanavir, saquinavir, darunavir, indinavir, nelfinavir Moderate CYP3A4/PgP inhibitors Erythromycin AUC ↑4.4-fold Use caution when (range 2.0-12.6) co-administration of moderate Cmax ↑2.0-fold CYP3A4 inhibitors or PgP (range 0.9-3.5) inhibitors cannot be avoided. If Imatinib AUC ↑ 3.7-fold patients require co-administration Cmax ↑ 2.2-fold of a moderate CYP3A4 or PgP Verapamil AUC ↑3.5-fold inhibitor, dose reduction to 5 mg (range 2.2-6.3) daily or 2.5 mg daily may be Cmax ↑2.3-fold considered. However, there are no (range1.3-3.8) clinical data with this dose Ciclosporin oral AUC ↑2.7-fold adjustment. Due to between (range 1.5-4.7) subject variability the Cmax ↑1.8-fold recommended dose adjustments (range 1.3-2.6) may not be optimal in all Cannabidiol (PgP inhibitor) AUC ↑2.5-fold individuals, therefore close Cmax ↑2.5-fold monitoring of side effects is Fluconazole Not studied. Increased exposure recommended (see sections 4.2 and Diltiazem expected. 4.4). If the moderate inhibitor is Dronedarone Not studied. Increased exposure discontinued, consider a washout expected. period of at least 2 to 3 days Amprenavir, fosamprenavir Not studied. Increased exposure (average elimination time for most expected. commonly used moderate inhibitors) before the Afinitor dose is returned to the dose used prior to initiation of the co-administration. Grapefruit juice or other Not studied. Increased exposure Combination should be avoided. food affecting CYP3A4/PgP expected (the effect varies widely).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) diltiazem (HOS-086288) nefazodone (HOS-084519) atazanavir (HOS-086180) nelfinavir (HOS-084520) dronedarone (HOS-086144) ketoconazole (HOS-084513) grapefruit juice (HOS-088787) cannabidiol (HOS-090609) imatinib (HOS-110212) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) darunavir (HOS-086181) fosamprenavir (HOS-086182) ritonavir (HOS-084521) posaconazole (HOS-085622) verapamil (HOS-090602)